Role of transforming growth factor (TGF)-pl in experimental chronic cyclosporine nephropathy. The pathogenesis of fibrosis in chronic cyclosporine (CsA) nephropathy remains unknown. Since TGF-f31 plays a key role in the fibrogenesis of a number of renal diseases, we studied a salt-depleted rat model of chronic CsA nephropathy which shows similarity to the structural and functional lesions described in patients. Pair fed rats were treated with either CsA (15 mg/kg/day s.c.) or an equivalent dose of olive oil and sacrificed at 7 and 28 days. Characteristic histologic changes of proximal tubular injury, tubulointerstitial fibrosis and arteriolopathy developed in CsA-treated rats at day 28. They were accompanied by physiologic changes of increased serum creatinine, decreased creatinine clearance, increased enzymuria and decreased concentrating ability. CsAtreated rats showed a progressive increase in mRNA expression of TGF-1 and matrix proteins at days 7 and 28. Most of the changes were in the tubulointerstitial and vascular compartments by immunofluorescence with a predominant involvement of the medulla as compared to cortex. The mRNA expression of plasminogen activator inhibitor, a protease inhibitor stimulated by TGF-pl, followed TGF-/31 and matrix proteins, suggesting that the fibrosis of chronic CsA nephropathy likely involves the dual action of TGF-p on matrix deposition and degradation.
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The introduction of cyclosporine A (CsA) into clinical practice has resulted in a major improvement in the short term outcomes of solid organ transplantation [1] and the treatment of autoimmune diseases [2] . However, with increased use has come the recognition that CsA has severe deleterious effects on renal structure and function making chronic nephrotoxicity a major limiting side effect [3] . Acute renal dysfunction due to CsA is reversible since it involves renal hemodynamic dysfunction and is not associated with any permanent histologic changes [4] . On the other hand, chronic CsA nephrotoxicity may progress to an irreversible renal lesion characterized by striped interstitial fibrosis, tubular atrophy and hyalinosis of the afferent arterioles [5, 6] .
Chronic CsA nephrotoxicity has been described in kidneys of recipients of renal and other organ allografts, as well as in patients treated with CsA for autoimmune diseases [7] [8] [9] . In addition, progression to end-stage renal disease with chronic CsA use is well documented [10] . However, the exact mechanism underlying the development of fibrosis in chronic CsA nephrotoxicity remains poorly understood [11] . The observed striped interstitial fibrosis does not improve consistently with discontinuation of the drug and occurs even in patients treated with low doses of CsA [6] .
Because the fibrotic lesion of chronic UsA nephrotoxicity has been difficult to reproduce in animals, the lack of an animal model of chronic CsA nephrotoxicity has hampered the study of its pathogenesis. Using the observation that sodium depletion exacerbates CsA nephrotoxicity, a reproducible animal model of chronic CsA nephrotoxicity was recently established [12] . In this model, CsA treatment in rats on low salt diet induced physiologic and histologic features that resemble the human lesion described in patients on long-term CsA therapy [13] . To date, no study has looked at the components of the fibrotic lesion of chronic UsA nephrotoxicity in vivo and none has attempted to correlate the renal fibrosis or the expression of ECM components with any growth factor, Transforming growth factor-p (TGF-/3) has been implicated in the fibrosis of a number of chronic diseases of the kidney and other organs [14, 15] . TGF-f3 directly stimulates the synthesis of individual ECM components [16] [17] [18] . It also blocks ECM degradation by decreasing the synthesis of proteases and stimulating protease inhibitors like plasminogen activator inhibitor-i (PAl-i) [19] . In addition to its effect on matrix accumulation, TGF-/3 also promotes immune suppression [20, 21] . Since TGF-13 is a key fibrogenic cytokine, we hypothesized that period, 24-hour quantitative urine samples were collected in metabolic cages (Nalge Co., Rochester, NY, USA) and systolic blood pressure (BP) was measured by tail plethysmography (Narco Bio-systems, Houston, TX, USA). The following day animals were anesthetized with ketamine and a blood sample was obtained. After opening the abdomen through a midline incision, the abdominal aorta was cannulated retrogradely below the renal arteries with an 18-gauge needle. With the aorta occluded by ligation above the renal arteries and the renal veins opened by a small incision for outflow, the kidneys were perfused with 20 ml of cold heparinized saline. The kidneys were removed, the cortex was carefully dissected from the medulla, and the tissues were processed for evaluation by light microscopy, RNA analysis and immunohistochemistry.
Functional studies
Urinary and plasma sodium were measured by flame photometer (Instrumentation Laboratories, Lexington, MA, USA). Urinary and plasma osmolality were measured by freezing point depression (Osmette A, Precision Systems Inc., Natick, MA, USA). Urinary and serum creatinine, urinary protein (Uprot), urinary alanine aminopeptidase (AAP) and urinary N-acetyl /3-D-glucosaminidase (NAG) were measured by a Cobas autoanalyzer (Roche Diagnostics, Div. Hoffman-La Roche Inc., Nutley, NJ, USA). CsA blood levels were determined in whole blood by a specific radioimmunoassay (Incstar Corp., Stillwater, MN, USA). The creatinine clearance (Ce,.), fractional excretion of sodium (FENa) and free water reabsorption (TcW) were calculated using standard formulae.
Morphology
Renal tissue samples were fixed in 10% buffered formalin and embedded in paraffin. Two to four micron thick sections were stained with periodic acid-Schiff's reagent (PAS) and Trichrome. Horizontal and sagittal sections were both performed. The histologic findings were subdivided into three categories: proximal tubular injury, interstitial inflammation and scarring, and arteriolopathy. Findings ascribed to tubular injury included cellular and intercellular vacuolization, tubular collapse (unassociated with interstitial fibrosis or tubular membrane thickening) and tubular distention. Features of interstitial inflammation were mononuclear infiltrates, edema and vacuolization of interstitial cells. The findings of scarring were matrix-rich expansion of the interstitium with distortion of the tubules and thickening of the tubular basement membranes. Renal arteriolopathy in chronic CsAinduced nephrotoxicity was characterized by hyalinization and destruction of the afferent arterioles. The hyalinosis consisted of hyalin deposition within the tunica media of afferent arterioles and terminal portion of interlobular arteries. A minimum of 20 fields at lOOx magnification were assessed and graded in each biopsy by an observer masked to treatment groups using a color image analyzer (Olympus CIA-102, Olympus Inc., Tokyo, Japan).
The following semiquantitative score was used to asses the extent of changes in each category. For tubular injury, the following score was utilized: 0 no tubular injury; 0.5 = <5% of 
RNA analysis
After separating the cortex from the medulla, the tissue was finely minced with a razor blade on ice. Total RNA was prepared by lysis in 4 M guanidine isothiocyanate containing 1% 2-mercaptoethanol and 0.5% lauryl sarcosyl and ultracentrifugation of the lysate on a cesium chloride cushion. After resuspending in
Tris-EDTA buffer, RNA concentrations were determined using spectrophotometric readings at Absorbance260. Thirty micro- were crosslinked by ultraviolet irradiation (Stratagene, La Jolla, CA, USA A mouse TGF-/31 cDNA probe (plasmid MUI5) was kindly provided by R. Deiynck [22] . A rat PAl-I cDNA probe [plasmid pBluescript SK(-)] was obtained from T.D. Gelehrter [23] .
Plasmid P16, which contains a human biglycan insert, was a gift of L.W. Fisher [241. A rat decorin cDNA probe (plasmid pGEM4) was provided generously by K.L. Dreher [25] . A rat procollagen al cDNA (plasmid paiRl) was obtained from D. Rowe [261. A rat GAPDH cDNA probe (plasmid pBluescript KS II) was a gift from J.M. Blanchard [27] .
Immunohistochemistiy
Immunofluorescence microscopy was performed on tissues snap frozen in cold isopentane with a clyostat microtome (Miles Scientific, Naperville, IL, USA) as previously described [28] . Four micrometer cryostat sections were fixed in acetone and washed in PBS, pH 7.4. The deposition of the following ECM components, decorin, tenascin and fibronectin-cellular containing extra domain A (fibronectin EDA+) was performed. The primary antibody for decorin was a rabbit anti-human decorin antibody and was provided by E. Ruoslahti (La Jolla, CA, USA) [29] . The other primary antibodies used were rabbit anti-human tenascin (Life Technologies, Gaithersburg, MD, USA) and mouse anti-human fibronectin EDA+ (Sera-lab, Crowley Down, UK). The secondary antibodies used were fluorescein isothiocyanate (FITC)-conjugated F(ab')2 donkey anti-rabbit IgG (Jackson Immunoresearch, West Grove, PA, USA) and FITC-conjugated F(ab')2 rat antimouse IgG (Jackson Immunoresearch). A minimum of 20 randomly selected areas per sample were observed at X250 magnification. The severity of staining for the glomerular, tubulointerstitial and vascular compartments was evaluated by an observer blinded to the treatment groups using the following semiquantitative scale: 0 = diffuse, very weak or absent staining, 1 = staining involving less than 25%, 2 = staining involving 25% to 50%, 3 = staining involving 50% to 75% and 4 = staining involving 75% to 100%. Photographs were obtained at identical exposure and development time intervals.
Statistical analysis
Results are presented as mean SEM. Multiple comparisons were done by analysis of variance. Comparisons between CsA and VH animals were done by two-tailed unpaired Student's t-test or 
Results

Physiologic studies
Although weight gain was progressive in the two treatment groups, animals treated with CsA failed to gain as much weight as those receiving vehicle (VH) with the difference achieving statistical significance (P < 0.01) at day 28. CsA-induced hypertension was not observed in this model; in fact, in CsA-treated rats, mean systolic BP tended to be numerically lower than in VH-treated rats, although the difference was not statistically significant. There was a progressive increase in CsA whole blood level in CsAtreated animals: 2930 250 ng/ml at day 7 and 5827 301 ng/ml at day 28.
CsA induced a significant increase in serum creatinine (Sr) only at day 28 (P < 0.01) ( Table 1) . On the other hand, the Cc1.
was already lower in the CsA-treated rats at day 7 (P < 0.05) and was progressively lower at day 28 (P < 0.01) ( Table 1 ). There was no significant proteinuria in the CsA-treated rats or the placebo animals.
The fractional excretion of sodium (FENa) was significantly decreased compared to normal in CsA-treated and placebo animals at all time points, reflecting the low sodium diet (Table 1) . CsA caused an increase in the urinary excretion of AAP at days 7 and 28 that was significant at day 7 (P < 0.01; Table 1 ). Urinary NAG excretion was also higher at both time intervals, but did not reach statistical significance (Table 1) . Urinary concentrating ability was clearly impaired as indicated by the progressive and significant increase in urinary volume by day 28 (P < 0.01) and decrease in U0sm by day 7 (P <0.05) and day 28 (P < 0.01) ( Table   1 ). There was also a decrease in TcW at both time intervals, although it was statistically significant only at day 7 (P < 0.05; Table 1 ).
Histologic changes
CsA-treated rats had characteristic morphologic findings similar to the chronic human lesion, mostly evident at day 28. There was a mononuclear cell infiltrate and an early tubular injury by day 7. However, the typical lesion of chronic CsA nephrotoxicity was observed by day 28 (Fig. 1) . (Table 2 ) using a 0 to 3 + semiquantitative scale, with 3 + indicating extensive changes. In this model, while no early histologic changes were observed by day 7, changes of chronic CsA nephrotoxicity manifested as proximal tubular injury, tubulointerstitial fibrosis and arteriolopathy developed by 28 days (P < 0.01) when compared to VH-treated rat kidneys.
Expression of TGF-131 and PAl-i mRNA TGF-pl mRNA was progressively increased by day 7 (P < 0.00 1) and more so at day 28 (P < 0.001) in the CsA-treated rats when compared to control VH rats (Figs. 2 and 3) . The mRNA expression of PAl-i, a protease inhibitor that blocks ECM degradation by the plasmin protease system and is directly stimulated by TGF-f3, is shown in Figures 2 and 4 . PAl-i mRNA, in parallel to TGF-f31 mRNA expression, was progressively up-regulated in the CsA-treated rats at seven days (P < 0.001) and more so at 28 days (P < 0.001) as compared to control VH rats (Fig. 4) .
Extracellular matrix deposition in the kidney Northern blot analysis. The proteoglycans biglycan and decorin are components of the ECM. Their mRNA expression was early expression of fibronectin EDA+ at day 7 (P < 0.001) that decreased by day 28 to control level. The deposition of decorin followed its mRNA expression and that of tenascin and fibronectin EDA+ (Figs. 7 and 8) . Most of the changes were observed at day 7 in the vessels (P < 0.001) and tubulointerstitium (P < 0.001) with no elevated expression in the glomeruli when compared to VH controls.
Differential expression in cortex and medulla
The differential expression in the cortex versus the medulla for TGF-/31, PAt-I and the ECM proteins was examined by Northern blots. As shown in Figure 9 , the changes observed in mRNA expression for TGF-/31, PAl-i, type I collagen and the proteoglycans, biglycan and decorin, although present in the cortex, was more dramatic and significant (P < 0.001) in the medulla as compared to the cortex at both days 7 and 28. I is normally present in the interstitial compartment of the kidney and is directly increased by TGF-13. In this model, the mRNA expression of type I collagen followed TGF-131 and PAl-i mRNA expression and was progressively up-regulated at day 7 (P <0.005 for cortex and < 0.001 for medulla) and day 28 (P < 0.001; Fig.   6 ).
Immunohistochemisity. Certain components of the ECM were also examined by immunotluorescence in order to assess whether the increased mRNA expression of matrix proteins was translated into increased protein synthesis and deposition into matrix. This allowed us to assess which compartments of the kidney (glomeruli, vessels or tubulointerstitium) were most extensively involved in matrix expansion. We examined the expression of tenascin, fibronectin EDA+, and decorin. The amount of tenascin and fibronectin EDA+ was elevated in the kidneys of CsA-treated rats as compared to VH controls at both days 7 and 28 in all the kidney compartments (Figs. 7 and 8) .
The changes were most significant in the tubulointerstitium for both tenascin (P < 0.005 at days 7 and 28) and fibronectin EDA+ (P < 0.005 at day 7 and < 0.01 at day 28; Fig. 8 ). The arteriolar hyalinosis observed in this model correlated with a progressive and significant increase in the expression of tenascin and fibronectin EDA+ in the vascular compartment of the kidneys of CsAtreated rats. While it was significant for fibronectin EDA+ at day 7 (P < 0.005) and day 28 (P < 0.005), the expression of tenascin did not reach statistical significance until day 28 (P < 0.01) when compared to VH controls (Fig. 7) . Most of the changes reached statistical significance in the tubulointerstitium and vascular compartments of the kidney, in accordance with the characteristic histology of chronic CsA nephrotoxicity (Fig. 8) . In the glomeruli, none of the changes were statistically significant except for an This report describes an animal model of chronic CsA nephrotoxicity that mimics the functional and histopathological findings observed in the human lesion of chronic-CsA induced injury. Salt-depletion has been shown to accelerate CsA nephropathy with the lesion developing by three to four weeks in the rat [12] instead of three months or longer [30] . In this model, we found that the histologic changes were accompanied by physiologic changes namely increased creatinine, decreased creatinine clearance, increased tubular enzymuria, and a loss of medullary concentrating ability. While enzymuria stabilizes, the other physiologic markers of CsA toxicity progress with continued treatment.
The matrix expansion observed in this model was most marked in the interstitial and vascular compartments of the kidney. This is in accordance with the characteristic histology of chronic CsA nephropathy that is interstitial fibrosis and arteriolopathy [5] .
Although present in the cortex, the observed changes were mostly in the medulla and were manifested by a dramatic increase in the presence of TGF-pl, PAl-i and matrix proteins. These changes were associated with a decrease in medullary concentrating ability. In accordance with our observation, recent data have shown that the early changes of CsA nephropathy are first seen in the medullary compartment of the kidney [31, 32] .
The common belief is that the chronic form of CsA injury is a consequence of CsA-induced renal vasoconstriction. According to this notion, the arteriolar vasospasm with resultant impairment in renal blood flow leads to tubulointerstitial fibrosis. Data to support the role of ischemia as a primary stimulus for tubulointerstitial fibrogenesis have been offered [33] . However, more recent studies have suggested that there can be a dissociation between the functional and histological injuries induced by CsA [13] . CsA withdrawal led to improved GFR but the degree of tubular atrophy and interstitial fibrosis actually progressed [13] . In our model, while acute tubular enzymuria stabilized, the associated histologic changes continued to progress during the follow-up period and were dominated by renal fibrosis. Our findings also indicate that the observed fibrosis was associated with an increased deposition of the three major components of the ECM: proteoglycans, glycoproteins, and collagens. mRNA was shown to be elevated in the renal cortex of CsAtreated rats [361. CsA was also recently shown to enhance TGF-p mRNA expression in normal human T cell culture [37] . Another cytokine, platelet-derived growth factor (PDGF), was shown to be present in the arteriolar walls of CsA-treated rats [38] . However, while most of the experiments done were in vitro, no study has looked at the components of the fibrotic lesion of chronic CsA nephrotoxicity in vivo, and none has attempted to correlate the renal fibrosis with any growth factor. Transforming growth factor-n (TGF-13) has been implicated in the fibrosis of a number of chronic diseases of the kidney and other organs [14, 15] . In addition, it is known to induce its own production [39] and its persistent expression following repeated injuries can lead to a cycle of continued TGF-/3 production [14] .
TGF-13 causes fibrosis by stimulating synthesis of individual ECM components and simultaneously blocking ECM degradation [16] [17] [18] [19] . In this model, we have observed an elevated expression of representative members of the proteoglycans, glycoproteins and collagen families. Their expression correlated with a parallel and significant increase in TGF-131. In addition, the protease inhibitor PAl-i was up-regulated and its expression followed closely the expression of TGF-pl and the ECM proteins studied. Since TGF-f31 directly stimulates PAl-i expression [19] , our data suggest that the observed ECM accumulation in this model likely involves the dual action of TGF-13 on ECM deposition and degradation.
What causes the elevation of TGF-13 remains unclear. Since CsA directly stimulates TGF-p in vitro, it has been proposed that the immune suppressive activities and renal fibrosis due to CsA are both mediated by TGF-13 [37, 40, 411 and may explain the elevated expression of TGF-131 in our model. It is also possible that renal ischemia produced by the vasoconstriction of CsA elevates TGF-/3 [42] . Since the current model is produced by salt-depletion, the renin-angiotensin system (RAS) is activated [32] . Interestingly, there is evidence to suggest that activation of the RAS up-regulates TGF-f3. The renal RAS is induced by CsA and plays an important role not only in the regulation of glomerular hemodynamics but also in glomerular growth and sclerosis [431. Angiotensin (Ang) II and CsA have been separately shown to stimulate fibrogenesis by mechanisms independent of their vasoconstrictive action [33, 44] . Chronic infusion of Ang II in rats produce considerable interstitial fibrosis [45] . Ang converting enzyme inhibitors and Ang II receptor antagonists attenuate interstitial fibrosis and progressive glomerulosclerosis in several disease models and slow disease progression in several human studies [46, 47] . Kagami et al have recently demonstrated a link between Ang II and TGF-/3 by showing that Ang II stimulation of ECM protein synthesis in rat glomerular mesangial cells is mediated by both an increase in TGF-/3 synthesis and an increase in the conversion from latent to active TGF-p [48] . In addition, CsA administration in salt-depleted rats caused a significant increase in juxtaglomerular (JG) apparatus renin, and blockage of the RAS with a competitive Ang II receptor antagonist, losartan, reduced the formation of interstitial fibrosis [49] . While the peripheral renin activity is often normal or suppressed in CsAtreated renal transplants, there is abundant evidence of JG cell hyperplasia within the kidney in such individuals similar to other one-clip, one-kidney models of hypertension [50] .
In conclusion, by using a model of chronic CsA nephropathy that mimics the human lesion, we have shown that matrix proteins are increased, mostly in the medulla, and more specifically in the interstitial and vascular compartments of the kidney. We have linked the expression of TGF-/31 to matrix expansion and have shown that both TGF-131 and PAl-I are increased. We propose that TGF-/31 is a key fibrogenic cytokine involved in the development of chronic CsA nephropathy by enhancing ECM deposition and inhibiting its degradation. However, other factors may also be involved in the fibrosis of chronic CsA nephrotoxicity. Whether long-term immunosuppression with CsA inevitably leads to renal fibrosis is unknown and has not been excluded by any properly controlled clinical study.
